October 30, 2020 LATITUDE Pharmaceuticals Receives Grant to Develop a Small-Volume Injectable Formulation for Remdesivir
May 06, 2020 LATITUDE Pharmaceuticals Develops an SC/IM Injectable Remdesivir Formulation
Jan 17, 2019 LATITUDE Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Stabilized Aqueous Glucagon Formulations
Sep 20, 2016 LATITUDE Pharmaceuticals Receives USPTO Notice of Allowance for Novel Injectable Depot Formulation Platform
Mar 03, 2016 LATITUDE Pharmaceuticals’ Nano-E and PG Depot Featured in March 2016 Issue of Drug Development & Delivery
Jan 11, 2016 LATITUDE Announces New Chinese Patent Granted to Nanoemulsion Composition Containing Vitamin K
Dec 01, 2015 LATITUDE Hires Senior Director of Business Development
Nov 09, 2015 LATITUDE Announces Recent Chinese Patent granted to PG Depot
Sep 20, 2015 Cidara Therapeutics Presents Poster on Novel Echinocandin CD101 Gel Formulation by LATITUDE at ICAAC/ICC 2015
Jun 20, 2013 JDRF Announces Two Partnerships to Develop Stable, Pumpable Glucagon
Mar 18, 2013 Helmsley Press Release T1D funding
Apr 03, 2012 LATITUDE Pharmaceuticals, Inc. Develops a Stable Liquid Glucagon Formulation
Apr 14, 2010 LATITUDE Pharmaceuticals Initiates Four Additional Collaboration Studies For Its PG Depot
Sep 15, 2009 Nano-E Antibacterial Emulsion Poster 49th ICAAC Annual Meeting
Jul 16, 2009 LATITUDE Signs Two More Collaboration Studies for PG Depot
May 12, 2009 Nanoemulsions are a Superior Approach to Formulating Insoluble IV Drugs
May 07, 2009 ADVENTRX Announces Results form ANX-514 Bioequivalence Trial
May 16, 2008 ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
May 10, 2008 Novalar Receives FDA Approval For OraVerse
